Multiple sclerosis (MS) is an autoimmune-mediated disease of the central nervous system
characterized by inflammation, demyelination and chronic progressive neurodegeneration …

Background Relapsing multiple sclerosis (RMS) is a chronic, inflammatory disease of the
central nervous system. Ublituximab, an anti-CD20 monoclonal antibody (mAb), is indicated …

Background Current guidelines recommend that individuals with MS are screened annually
for processing speed deficits, often using the Symbol Digit Modalities Test (SDMT) …

Background Fatigue, depression and sleep problems are among the most common
symptoms in patients with multiple sclerosis (PwMS) and are correlated with each other. In …

Background Alemtuzumab is a humanized monoclonal antibody approved for the treatment
of relapsing-remitting multiple sclerosis (RRMS). Its efficacy and safety have been widely …

Background In relapsing–remitting multiple sclerosis (RRMS) the connection between
cognitive impairment (CI) and white matter lesion load (WM-LL) and location is still unclear …

Background Cognitive dysfunction is frequently seen in multiple sclerosis (MS). However,
there are conflicting findings regarding the factors it is associated with. Objective To …

Multiple sclerosis (MS) is characterized by a variety of symptoms that have a major impact
on quality of life (QoL) even in early stages. In addition to individual motor, sensory, visual …

In the world, the prevalence of chronic diseases has had significant statistics that this factor
has had negative effects and complications on the quality of life of patients [1-4]. In fact …

Multiple sclerosis (MS) is the most common non-traumatic debilitating disease [1] that affects
young adults [2]. MS is a chronic inflammatory disorder of the central nervous system in …